
Anondita Medicare Limited Qualified as Vendor for Condom Supply to Government of South Africa
Anondita Medicare Limited has successfully been qualified as a vendor and supplier for the manufacture and supply of condoms and lubricants to the Government of South Africa. This achievement follows the company's successful completion of due diligence processes and an audit by the South African Bureau of Standards (SABS).The qualification allows Anondita Medicare Limited to supply products to local entities operating under the National Treasury, Republic of South Africa, through the Transversal Contract RT75-2025.
The contract mandates the supply and delivery of condoms and lubricants to the state over a significant period, running from November 1, 2025, through October 31, 2030. This long-term contract aims to ensure uninterrupted product availability and mitigate potential supply delays for the government.
As part of the required selection process, an audit was conducted by the South African Bureau of Standards (SABS) on April 20, 2026. This audit assessed the company's manufacturing capacity, product samples, and adherence to quality standards. SABS is expected to submit its audit report to the National Treasury, South Africa, for further action.
Following its addition as a vendor, Anondita Medicare Limited will execute formal agreements with the South African Local Entities that have been awarded the tender under Transversal Contract RT75-2025. These local entities will then issue purchase orders (POs) to facilitate the supply and delivery of condoms and lubricants.
ANONDITA Stock Price Movement
Anondita Medicare Limited shares today slipped by 5.00% to settle at ₹1130.45. The stock traded on a volume of 19,000 shares, closing near its day's low of ₹1130.45.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.